Here, targeted LNPs consisting of a novel ionizable cationic lipid were generated to target CD38, an overexpressed glycoprotein on MM cells, and encapsulated with siRNA to demonstrate their therapeutic potential. This evidence concerns the gene ART4 and Miyoshi myopathy.